(ADXS)—IOVA* doses first patient in cervical-cancer phase-2: https://globenewswire.com/news-release/2017/08/16/1086553/0/en/Iovance-Biotherapeutics-Announces-First-Patient-Dosed-in-C-145-04-Phase-2-Trial-in-Cervical-Cancer.html *f/k/a LBIO.